{"eventGroups":[{"deathsNumAffected":8,"deathsNumAtRisk":24,"description":"* Rituximab 375 mg/m2 IV day1\n* Cladribine 4 mg/m2 IV over 2 hours days 1-5\n* Bortezomib 1.3 mg/m2 IV days 1 and 4\n* Repeat every 28 days for a maximum of 6 cycles\n\nrituximab: 375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.\n\nbortezomib: 1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.\n\ncladribine: 4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.","id":"EG000","otherNumAffected":24,"otherNumAtRisk":24,"seriousNumAffected":14,"seriousNumAtRisk":24,"title":"VCR (Velcade, Cladribine and Rituximab)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":24}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":24}],"term":"Fever"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24}],"term":"Neuropathy"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":24}],"term":"Thrombocytopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":24}],"term":"Neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":24}],"term":"Anemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24}],"term":"Dyspnea"}],"timeFrame":"107 months"}